A 2011 study, however, noted that p300 is under-expressed in doxorubicin-resistant bladder cancer cells, generating interest in this class as a potential therapeutic target for chemotherapy-resistant cancers [30]. This evidence concerns the gene EP300 and urinary bladder cancer.